AI technical title is built by Patsnap AI team. It summarizes the technical point description of the patent document.
An antibody, anx-a1 technology, applied in the fields of monoclonal antibodies and fragments thereof, preparations and compositions comprising specific binding molecules
Pending Publication Date: 2019-11-19
MEDANNEX LTD
View PDF6 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Humanized VJ-4B6 antibody can
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0211] Example 1: Sequencing of Anx-A1 binding antibody produced by hybridoma ECACC 10060301
[0212] mRNA was extracted from hybridoma ECACC 10060301. The extracted mRNA was transcribed into cDNA using a reverse transcription protocol. The cDNA was sequenced by standard dye-terminator capillary sequencing from Aldevron (USA) using proprietary primers.
[0213] use Terminator v3.1 Cycle Sequencing Kit, at Life Cycle sequencing was performed under the standard protocol provided. All data were obtained using the 3730xl DNA Analyzer System and Life Collected by the supplied Unified Data Collection Software, which is used to operate the 3730xl DNA Analyzer and collect data generated by the 3730xl DNA Analyzer.
[0214] Sequence assembly was performed using CodonCode Aligner (CodonCode Corporation, USA). Resolve mixed base calls by automatically assigning the most prevalent base calls to mixed base calls. Prevalence is determined by the frequency of base calls and the i...
Embodiment 2
[0217] Example 2: Production of Anx-A1 binding Mdx001 antibody
[0218] The codon-optimized sequence was cloned into vector pD2610-v13 (ATUM, USA) using standard recombination techniques and transfected into ExpiCHO cells (Thermo Fisher Scientific, USA). A 200ml culture was produced. Antibody (Mdx001) was recovered from cell supernatant using a protein A affinity column and eluted into phosphate buffered saline.
Embodiment 3
[0219] Example 3: Mdx001 Binding to Anx-A1
[0220] Binding of Mdx001 to Anx-A1 was confirmed by ELISA performed by The Antibody Company (UK) using standard ELISA techniques. ELISA plate with 25μg / ml Anx-A1 and coating buffer (45mM Na 2 CO 3 , pH 9.6, supplemented with 1 mM CaCl 2 ) was coated overnight at 4°C (found Ca 2+ is required for the binding of Mdx001 to Anx-A1, so all binding experiments were performed at 1 mM CaCl 2 in presence. )
[0221] Then, the plate was incubated at room temperature with blocking buffer (1 mM CaCl 2 , 10mM HEPES, 2% w / v BSA) for blocking for 1 hour. Then, the primary antibody (Mdx001) was applied to the plate. Antibodies were applied in duplicate in quadruple dilutions prepared across the plate, starting at a concentration of 1 μg / ml and ending at 2.38 × 10 -7 End of concentration in μg / ml. Dilute the antibody in wash buffer supplemented with 0.1BSA (10mM HEPES, 150mM NaCl, 0.05% (v / v) Tween-20 and 1mM CaCl 2 )middle. The primary...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The present invention relates to an isolated specific binding molecule which binds human Anx-A1and comprises the complementarity-determining regions (CDRs) VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2 and VHCDR3, wherein each of said CDRs has an amino acid sequence as follows: VLCDR1 has the sequence set forth in SEQ ID NO: 1, 36 or 37; VLCDR2 has the sequence set forth in SEQ ID NO: 2; VLCDR3 has the sequence set forth in SEQ ID NO: 3; VHCDR1 has the sequence set forth in SEQ ID NO: 4; VHCDR2 has the sequence set forth in SEQ ID NO: 5; and VHCDR3 has the sequence set forth in SEQ ID NO: 6; or, foreach sequence, an amino acid sequence with at least 85% sequence identity thereto. The specific binding molecule disclosed is therapeutically useful and in particular may be used in therapy for T-cellmediated diseases, including autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, obsessive compulsive disorder (OCD),and OCD-related diseases, such as anxiety disorders.
Description
technical field [0001] The present invention relates to specific binding molecules binding to human annexin A1 (Anx-A1), especially monoclonal antibodies and fragments thereof, and their use in the treatment of certain diseases. The invention also relates to nucleic acid molecules and the like encoding the specific binding molecules of the invention, as well as formulations and compositions comprising the specific binding molecules. Background technique [0002] In recent years, a number of research groups have demonstrated that Anx-A1 plays a homeostatic role in multiple cell types of both the innate and adaptive immune systems. For example, Anx-A1 has been shown to exert homeostatic control on cells of the innate immune system such as neutrophils and macrophages, and also functions in T cells by modulating the strength of T-cell receptor (TCR) signaling (D 'Acquisto et al., Blood 109:1095-1102, 2007). [0003] High levels of Anx-A1 lower the threshold of T cell activatio...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More